Serous endometrial cancers (ECs) are clinically aggressive tumors that frequently harbor somatic mutations in FBXW7 (F-box and WD repeat domain-containing 7). The 
genomic aberrations in serous ECs, clear cell ECs, and carcinosarcomas. FBXW7 is a tumor suppressor that serves as the substrate recognition subunit of a SCF (complex of SKP1, Cullin 1, F-box protein) ubiquitin ligase complex and has been implicated in the regulation of at least 35 substrates across cancer types, 14 many of which are oncoproteins. The FBXW7 gene encodes three primary isoforms (α, β, and γ) that differ only at the N-termini. 15 FBXW7α, the most abundant isoform, targets the most substrates that have been tested experimentally, and localizes to the nucleoplasm; the β and γ isoforms localize to the cytoplasm and nucleolus, respectively. 16 8, 18, 21, 27 Despite the high frequency of occurrence, little is known of the molecular consequences of FBXW7 mutations in ECs. Thus far only indirect correlations between increased Cyclin E protein and FBXW7
mutations have been shown, 15, 19 leading to speculation that FBXW7 mutations might dysregulate Cyclin E in EC. In keeping with this idea, one study reported that FBXW7 mutations and genomic deletions occur mutually exclusively of CCNE1 amplification in serous ECs, 19 although others found no association across histological subtypes of EC. 28 Herein, we provide novel insights into the functional consequences of FBXW7 mutations in serous EC cells. We show that recurrent somatic FBXW7 mutations cause increased levels of Laboratories, Inc., Montgomery, TX) overnight at 4°C at a dilution of 1:1000 in TBST + 5% milk after multiple freeze/thaws, following a previously published protocol. 30 We verified specificity of the antibody 
| Flow cytometry
Cells were plated in 6-well plates (2. 
| Statistical analyses
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Figures 1C and 1D ). In light of these observations and given that SRC-3 and Rictor can activate AKT [33] [34] [35] and that AKT activation can result in SRC-3 activation via inhibitory phosphorylation of GSK3, 36 we determined the effects of FBXW7α mutations on components of the AKT pathway. We found that phosphorylated GSK3, P70S6, and AKT proteins were increased in cells expressing 
| Compared to parental cells, CRISPR-edited FBXW7-mutant ARK1 cells exhibit decreased viability and increased apoptosis in response to SI-2 and dinaciclib
We hypothesized that the increased protein levels detected in association with FBXW7 mutations might promote sensitivity to Figure S4C) . In contrast, we found statistically significantly decreased viability in CRISPR-edited FBXW7-mutant ARK1 cells compared to parental cells in response to SI-2 and dinaciclib.
SI-2 is a small molecule SRC inhibitor that selectively targets SRC-3 over SRC-1 or −2. G2/M did not significantly decrease in response to dinaciclib treatment ( Figure 6A ). As expected, dinaciclib treatment decreased levels of phosphorylated Rb, as well as other cell cycle proteins, compared to levels in DMSO-treated cells ( Figure 6B ). Interestingly, in the absence of dinaciclib, p53 protein levels were increased in FBXW7-mutant ARK1 cells compared to parental cells ( Figure 6B ). In summary, these findings indicate that CRISPR-edited FBXW7-mutant ARK1 cells exhibit increased sensitivity to SI-2 and dinaciclib compared to 
| DISCUSSION
Despite the high prevalence of somatic FBXW7 mutations in ECs, particularly in clinically aggressive subtypes such as serous and clear cell ECs, as well as uterine carcinosarcomas, the molecular consequences of these mutations in the context of EC remain unknown.
Here, we used transient transfection and CRISPR-editing to interrogate the molecular effects of FBXW7 mutations in serous EC cell lines.
We show that FBXW7 mutations result in increased phosphorylated SRC-3, Cyclin E1, c-MYC, Rictor, GSK3, AKT, and P70S6 protein levels.
Furthermore, we provide in vitro evidence of increased sensitivity of FBXW7-mutant serous EC cells to SI-2, a SRC inhibitor, and dinaciclib, a CDK inhibitor.
SRC-3, also known as AIB1 and NCOA3, is a FBXW7 substrate 36 and oncoprotein that plays a role in integrating signals from a number of pathways important in tumorigenesis. 40 Phosphorylation of SRC-3
at Thr24, an event that we show is increased in association with FBXW7 mutation, is important for the interaction of SRC-3 with NF-KB, SRC-3 activity associated with IL-6 gene regulation and the transforming ability of SRC-3. 41 SRC-3 mRNA has been shown to be upregulated in EC compared to normal endometrium 42 and EC patients with higher SRC-3 mRNA expression have poorer prognoses compared to patients with relatively lower expression. 43 To our knowledge, the present study is the first to show an association Like SRC-3, Cyclin E1 is oncogenic upon dysregulation 44 and is a known FBXW7 substrate, 32, 45 but experimental evidence of direct association between FBXW7 mutation and increased Cyclin E1 protein levels in EC has not to our knowledge been described prior to the results provided herein. A previous study provided an indirect correlation by 33, 34 ; phosphorylated AKT can be induced by SRC-3 overexpression 35 and, inversely, can promote phosphorylated SRC-3 (Thr24) through GSK inhibitory phosphorylation (Ser9/21). 36 Future work is needed to determine if increases in Rictor, AKT, GSK3, and P70S6 protein levels associated with FBXW7 mutations reflect druggable changes.
A caveat of this study is that our search for molecular effects of These results indicate that increased MCL-1 protein levels are a molecular effect of FBXW7 mutation, but perhaps not of complete mutations. The implications of this study will also need to be tested in organoids or in vivo models.
In conclusion, the results presented herein provide new insights into the molecular effects of FBXW7 mutations in serous ECs. We identified increased levels of a number of phosphorylated proteins associated with recurrent FBXW7 mutations, most of which occur within druggable pathways. Furthermore, we provide in vitro evidence that FBXW7 mutations confer sensitivity to SI-2 and dinaciclib.
Combined, these novel biochemical results lay the groundwork for future studies to determine whether FBXW7 mutations represent an Achilles' heel that could be leveraged to improve the care of women suffering from clinically aggressive ECs.
